Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), according to 15-year outcomes presented by Barry Goy, MD, of Kaiser Permanente.
Despite clinical trial findings, real-world evidence shows adding 6 months of neoadjuvant deprivation therapy (NADT) to external-beam radiation therapy (EBRT) for patients with intermediate-risk prostate cancer did not improve prostate cancer–specific survival or overall survival, explained Barry Goy, MD, a radiation oncologist at Kaiser Permanente Los Angeles Medical Center.
Goy presented the findings of a retrospective analysis of 15-year outcomes of patients with intermediate-risk prostate cancer who were treated with EBRT with or without NADT.
This transcript has been lightly edited; captions were auto-generated.
Transcript
Your 15-year study found it's unclear if 6 months of neoadjuvant deprivation therapy added to external-beam radiation therapy improves survival of intermediate-risk prostate cancer. Are there any characteristics of patients who might benefit more and justify the use of neoadjuvant deprivation therapy?
Patients with visible metastases. Certainly, we are seeing more visible metastases these days than we used to because of the PSMA [prostate-specific membrane antigen] PET scan. I think in the older days—for the majority of my career—bone scan or CTs didn't pick up much of anything, so it was just a number. Just because you see a visible metastasis on PSMA PET scan that may not be so bad, because it's a very sensitive scan. It's almost closer to the PSA [prostate-specific antigen] level, as opposed to traditional imaging.
I think what's happening as a result of the PSMA PET scan, people are being treated more aggressively now than they used to be, even though we may not have clear evidence that we're improving prostate cancer–specific survival.
Would more information provide a more accurate picture of whether neoadjuvant deprivation therapy does provide a benefit?
I personally think 6 months of neoadjuvant deprivation therapy and additional radiation is not going to reduce prostate cancer–specific mortality. That's my personal opinion looking at the data—despite what the randomized trials show—and what I've seen over the years from my clinical experience. One shot [of therapy] to improve prostate cancer–specific survival that much [compared with no NADT] just really doesn't make sense to me.
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More